Crossmark

The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer

Crossref DOI link: https://doi.org/10.1245/s10434-016-5557-9

Published Online: 2016-09-08

Published Print: 2017-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kataoka, Masato

Kanda, Mitsuro

Ishigure, Kiyoshi

Matsuoka, Hiroshi

Sato, Yusuke

Takahashi, Takao

Tanaka, Chihiro

Deguchi, Tomohiro

Shibata, Yoshihisa

Sato, Mikinori

Inagaki, Hitoshi

Matsui, Takanori

Kondo, Akinori

Takano, Nao

Tanaka, Haruyoshi

Sakamoto, Junichi

Oba, Koji

Kondo, Ken
License Information

License valid from 2016-09-08

Updates are available Correction dated 2016-09-19

Click to view Correction: https://doi.org/10.1245/s10434-016-5593-5